That is below the 30% rate reported at an interim stage of the study at the International Liver Congress earlier this year, but still sufficient for GSK to take the drug forward into a phase 3 ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

Last year, GSK had 13 positive Phase 3 readouts a record achievement for ... a very promising and highly selective KIT tyrosine kinase inhibitor designed to treat gastrointestinal stromal tumors.

Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95 patients enrolled ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Reports Q4 revenue $7M, consensus $4.31M. The net loss for the three months ended December 31, 2024, was $130.3M compared to the net loss of ...

BIO CEO & Investor Conference Format: "IPO Class of 2024 Panel" and one-on-one meetings Date: February 10, 2025 Location: New York, NY Registered conference attendees may schedule one-on-one meetings ...

Analysts at RBC Capital Markets have predicted twice-yearly lenacapavir could become a $2 billion product, and become a key ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab ... with an average gain of +24.3% per year. So be sure to give ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation ...